Your browser doesn't support javascript.
loading
Definition, diagnosis and treatment of oligometastatic oesophagogastric cancer: A Delphi consensus study in Europe.
Kroese, Tiuri E; van Laarhoven, Hanneke W M; Schoppman, Sebastian F; Deseyne, Pieter R A J; van Cutsem, Eric; Haustermans, Karin; Nafteux, Philippe; Thomas, Melissa; Obermannova, Radka; Mortensen, Hanna R; Nordsmark, Marianne; Pfeiffer, Per; Elme, Anneli; Adenis, Antoine; Piessen, Guillaume; Bruns, Christiane J; Lordick, Florian; Gockel, Ines; Moehler, Markus; Gani, Cihan; Liakakos, Theodore; Reynolds, John; Morganti, Alessio G; Rosati, Riccardo; Castoro, Carlo; Cellini, Francesco; D'Ugo, Domenico; Roviello, Franco; Bencivenga, Maria; de Manzoni, Giovanni; van Berge Henegouwen, Mark I; Hulshof, Maarten C C M; van Dieren, Jolanda; Vollebergh, Marieke; van Sandick, Johanna W; Jeene, Paul; Muijs, Christel T; Slingerland, Marije; Voncken, Francine E M; Hartgrink, Henk; Creemers, Geert-Jan; van der Sangen, Maurice J C; Nieuwenhuijzen, Grard; Berbee, Maaike; Verheij, Marcel; Wijnhoven, Bas; Beerepoot, Laurens V; Mohammad, Nadia H; Mook, Stella; Ruurda, Jelle P.
Afiliação
  • Kroese TE; Department of Surgery, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands; Department of Radiation Oncology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands. Electronic address: https://twitter.com/TEKroese.
  • van Laarhoven HWM; Amsterdam UMC Location University of Amsterdam, Department of Medical Oncology, Amsterdam, the Netherlands; Cancer Center Amsterdam, Cancer Treatment and Quality of Life, Amsterdam, the Netherlands.
  • Schoppman SF; Department of Surgery, Medical University of Vienna, Vienna University, Vienna, Austria.
  • Deseyne PRAJ; Department of Radiation Oncology, Ghent University Hospital, Ghent, Belgium.
  • van Cutsem E; Department of Medical Oncology, KU Leuven, Leuven University, Leuven, Belgium.
  • Haustermans K; Department of Radiation Oncology, KU Leuven, Leuven University, Leuven, Belgium.
  • Nafteux P; Department of Surgery, KU Leuven, Leuven University, Leuven, Belgium.
  • Thomas M; Department of Radiation Oncology, AZ Sint Maarten, Mechelen, Belgium.
  • Obermannova R; Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute and Faculty of Medicine, Masaryk, University Brno, Brno, Czech Republic.
  • Mortensen HR; Danish Center of Particle Therapy, Aarhus University Medical Center, Aarhus University, Aarhus, Denmark.
  • Nordsmark M; Department of Radiation Oncology, Aarhus University Medical Center, Aarhus University, Aarhus, Denmark.
  • Pfeiffer P; Department of Medical Oncology, Odense University Medical Center, University of Odense, Odense, Denmark.
  • Elme A; Department of Medical Oncology, Tallinn University Hospital, Tallinn University, Tallinn, Estonia.
  • Adenis A; Department of Medical Oncology, IRCM, Inserm, Université Montpellier, ICM, Montpellier, France.
  • Piessen G; Department of Surgery, Univ. Lille, CNRS, Inserm, CHU Lille, UMR9020-U1277 - CANTHER - Cancer Heterogeneity Plasticity and Resistance to Therapies, F-59000 Lille, France.
  • Bruns CJ; Department of Surgery, University Hospital Cologne, University of Cologne, Cologne, Germany.
  • Lordick F; Department of Medical Oncology, University Hospital Leipzig, University of Leipzig, Leipzig Germany.
  • Gockel I; Department of Visceral, Transplant, Thoracic and Vascular Surgery, University Hospital Leipzig, University of Leipzig, Leipzig Germany.
  • Moehler M; Department of Medicine, Johannes Gutenberg-University Clinic, University of Mainz, Mainz, Germany.
  • Gani C; Department of Radiation Oncology, University Hospital Tubingen, University of Tubingen, Tubingen, Germany.
  • Liakakos T; Department of Surgery, Medical School, National and Kapodistrian University of Athens, Athens, Greece.
  • Reynolds J; Department of Surgery, St. James Hospital, Trinity College Dublin, Dublin, Ireland.
  • Morganti AG; Department of Radiation Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy; Department of Radiation Oncology, DIMES, Alma Mater Studiorum - Bologna University, Bologna, Italy.
  • Rosati R; Department of GI Surgery, San Raffaele Hospital, San Raffaele Vita-salute University, Milan, Italy.
  • Castoro C; Department of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini 4, 20072 Pieve Emanuele, Milan, Italy; Upper GI and General Surgery Division, Department of Surgery IRCCS Humanitas Research Hospital, Via Manzoni 56, 20089 Rozzano, Milan, Italy.
  • Cellini F; Università Cattolica Del Sacro Cuore, Dipartimento Universitario Diagnostica per Immagini,. Radioterapia Oncologica Ed Ematologia, Roma, Italy; Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Dipartimento di Diagnostica per Immagini, Radioterapia Oncologica Ed Ematologia, Roma, Italy.
  • D'Ugo D; Department of Surgery, Fondazione Policlinico Universitario Agostino Gemelli, Rome, Italy.
  • Roviello F; Department of Surgery, Siena University Hospital, University of Siena, Siena, Italy.
  • Bencivenga M; General and Upper GI Division, Department of Surgery, Dentistry, Paediatrics and Gynaecology, University of Verona, Verona, Italy.
  • de Manzoni G; General and Upper GI Division, Department of Surgery, Dentistry, Paediatrics and Gynaecology, University of Verona, Verona, Italy.
  • van Berge Henegouwen MI; Department of Surgery, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, the Netherlands; Cancer Center Amsterdam, Cancer Treatment and Quality of Life, Amsterdam, the Netherlands.
  • Hulshof MCCM; Department of Radiation Oncology, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, the Netherlands.
  • van Dieren J; Department of Gastroenterology, Antoni van Leeuwenhoek, Netherlands Cancer Institute, Amsterdam, the Netherlands.
  • Vollebergh M; Department of Medical Oncology, Antoni van Leeuwenhoek, Netherlands Cancer Institute, Amsterdam, the Netherlands.
  • van Sandick JW; Department of Surgery, Antoni van Leeuwenhoek, Netherlands Cancer Institute, Amsterdam, the Netherlands.
  • Jeene P; Department of Radiation Oncology, Radiotherapiegroep, Deventer, the Netherlands.
  • Muijs CT; Department of Radiation Oncology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.
  • Slingerland M; Department of Medical Oncology, University Medical Center Leiden, University of Leiden, Leiden, the Netherlands.
  • Voncken FEM; Department of Radiation Oncology, University Medical Center Leiden, University of Leiden, Leiden, the Netherlands.
  • Hartgrink H; Department of Surgery, University Medical Center Leiden, University of Leiden, Leiden, the Netherlands.
  • Creemers GJ; Department of Medical Oncology, Catharina Medical Center, Eindhoven, the Netherlands.
  • van der Sangen MJC; Department of Radiation Oncology, Catharina Medical Center, Eindhoven, the Netherlands.
  • Nieuwenhuijzen G; Department of Surgery, Catharina Medical Center, Eindhoven, the Netherlands.
  • Berbee M; Department of Radiation Oncology (MAASTRO), GROW School for Oncology and Developmental Biology, Maastricht, the Netherlands.
  • Verheij M; Department of Radiation Oncology, Radboud University Medical Center, Nijmegen, the Netherlands.
  • Wijnhoven B; Department of Surgery, Erasmus University Medical Center, University of Rotterdam, Rotterdam, the Netherlands.
  • Beerepoot LV; Department of Medical Oncology, Elisabeth Tweesteden Ziekenhuis Tilburg, the Netherlands.
  • Mohammad NH; Department of Medical Oncology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.
  • Mook S; Department of Radiation Oncology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.
  • Ruurda JP; Department of Surgery, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.
Eur J Cancer ; 185: 28-39, 2023 05.
Article em En | MEDLINE | ID: mdl-36947929
ABSTRACT

BACKGROUND:

Local treatment improves the outcomes for oligometastatic disease (OMD, i.e. an intermediate state between locoregional and widespread disseminated disease). However, consensus about the definition, diagnosis and treatment of oligometastatic oesophagogastric cancer is lacking. The aim of this study was to develop a multidisciplinary European consensus statement on the definition, diagnosis and treatment of oligometastatic oesophagogastric cancer.

METHODS:

In total, 65 specialists in the multidisciplinary treatment for oesophagogastric cancer from 49 expert centres across 16 European countries were requested to participate in this Delphi study. The consensus finding process consisted of a starting meeting, 2 online Delphi questionnaire rounds and an online consensus meeting. Input for Delphi questionnaires consisted of (1) a systematic review on definitions of oligometastatic oesophagogastric cancer and (2) a discussion of real-life clinical cases by multidisciplinary teams. Experts were asked to score each statement on a 5-point Likert scale. The agreement was scored to be either absent/poor (<50%), fair (50%-75%) or consensus (≥75%).

RESULTS:

A total of 48 experts participated in the starting meeting, both Delphi rounds, and the consensus meeting (overall response rate 71%). OMD was considered in patients with metastatic oesophagogastric cancer limited to 1 organ with ≤3 metastases or 1 extra-regional lymph node station (consensus). In addition, OMD was considered in patients without progression at restaging after systemic therapy (consensus). For patients with synchronous or metachronous OMD with a disease-free interval ≤2 years, systemic therapy followed by restaging to consider local treatment was considered as treatment (consensus). For metachronous OMD with a disease-free interval >2 years, either upfront local treatment or systemic treatment followed by restaging was considered as treatment (fair agreement).

CONCLUSION:

The OMEC project has resulted in a multidisciplinary European consensus statement for the definition, diagnosis and treatment of oligometastatic oesophagogastric adenocarcinoma and squamous cell cancer. This can be used to standardise inclusion criteria for future clinical trials.
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Tipo de estudo: Diagnostic_studies / Systematic_reviews Limite: Humans País/Região como assunto: Europa Idioma: En Ano de publicação: 2023 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Tipo de estudo: Diagnostic_studies / Systematic_reviews Limite: Humans País/Região como assunto: Europa Idioma: En Ano de publicação: 2023 Tipo de documento: Article